Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
97 participants
INTERVENTIONAL
2009-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells
NCT00410267
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
NCT06865144
PSLT Compared to Prostaglandin Analogue Eye Drops
NCT05241938
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00329095
Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?
NCT00853905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Artificial Tears
Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Artificial Tears
Artificial saline tears to lasered eye 4 times/day for 4.5 days
Non-steroidal anti-inflammatory
Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Ketorolac
Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
Steroid
Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Prednisolone 1%
Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prednisolone 1%
Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Ketorolac
Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
Artificial Tears
Artificial saline tears to lasered eye 4 times/day for 4.5 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinician has determined that SLT laser is indicated
* IOP currently \>18 and was ever \>21 in the past (e.g. prior to treatment)
Exclusion Criteria
* prior glaucoma surgery including glaucoma laser surgery
* pregnant or 3 months post-partum
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bascom Palmer Eye Institute
OTHER
University of Pittsburgh Medical Center
OTHER
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeffrey L Goldberg
Professor of Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey L Goldberg, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bascom Palmer Eye Institute
Miami, Florida, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20081142
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.